Drug Profile


Alternative Names: EVT-302; RG-1577; RO-4602522

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Evotec AG; Roche
  • Class Acetanilides; Nootropics; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Smoking withdrawal

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Sep 2016 Phase II development is ongoing in Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Korea, Spain, Sweden, United Kingdom and USA (Evotec pipeline, September 2016)
  • 30 Jun 2015 Interim efficacy and safety data from a phase-II trial in Alzheimer's disease released by Roche (NCT01677754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top